Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Identities ; 30(3):352-372, 2023.
Article in English | ProQuest Central | ID: covidwho-2324623

ABSTRACT

Drawing on longitudinal research with 33 Chinese international students in 10 European countries, this article examines their polymorphic identifications towards homeland and asks how these changing perceptions constitute the underlying logic of their particular migration aspirations during the COVID-19. Specifically, the article explores how homeland identifications function as a driving force to facilitate ‘voluntary immobility' in the study destination while being used as a tackling strategy to adapt to their ‘involuntary immobility' overseas. It also examines how these identifications articulate with the students' mixing and shifting migration aspirations formulated during the pandemic. In doing so, the article demonstrates that polymorphic perceptions closely relate to the generation, exercise and reproduction of their migration aspirations that are temporally distributed.

3.
Drug Des Devel Ther ; 16: 951-972, 2022.
Article in English | MEDLINE | ID: covidwho-1779832

ABSTRACT

The COVID-19 has plunged the world into a pandemic that affected millions. The continually emerging new variants of concern raise the question as to whether the existing vaccines will continue to provide sufficient protection for individuals from SARS-CoV-2 during natural infection. This narrative review aims to briefly outline various immunotherapeutic options and discuss the potential of clustered regularly interspaced short palindromic repeat (CRISPR Cas system technology against COVID-19 treatment as specific cure. As the development of vaccine, convalescent plasma, neutralizing antibodies are based on the understanding of human immune responses against SARS-CoV-2, boosting human body immune responses in case of SARS-CoV-2 infection, immunotherapeutics seem feasible as specific cure against COVID-19 if the present challenges are overcome. In cell based therapeutics, apart from the high costs, risks and side effects, there are technical problems such as the production of sufficient potent immune cells and antibodies under limited time to treat the COVID-19 patients in mild conditions prior to progression into a more severe case. The CRISPR Cas technology could be utilized to refine the specificity and safety of CAR-T cells, CAR-NK cells and neutralizing antibodies against SARS-CoV-2 during various stages of the COVID-19 disease progression in infected individuals. Moreover, CRISPR Cas technology are proposed in hypotheses to degrade the viral RNA in order to terminate the infection caused by SARS-CoV-2. Thus personalized cocktails of immunotherapeutics and CRISPR Cas systems against COVID-19 as a strategy might prevent further disease progression and circumvent immunity escape.


Subject(s)
COVID-19 Drug Treatment , COVID-19 , CRISPR-Cas Systems , Antibodies, Neutralizing , COVID-19/therapy , Disease Progression , Humans , Immunization, Passive , Immunologic Factors , SARS-CoV-2 , COVID-19 Serotherapy
4.
J Med Case Rep ; 15(1): 60, 2021 Feb 08.
Article in English | MEDLINE | ID: covidwho-1069584

ABSTRACT

BACKGROUND: To investigate the potential beneficial effect of fecal microbiota transplantation (FMT) on gastrointestinal symptoms, gut dysbiosis and immune status in discharged COVID-19 patients. CASE PRESENTATION: A total of 11 COVID-19 patients were recruited in April, 2020, about one month on average after they were discharged from the hospital. All subjects received FMT for 4 consecutive days by oral capsule administrations with 10 capsules for each day. In total, 5 out of 11 patients reported to be suffered from gastrointestinal symptoms, which were improved after FMT. After FMT, alterations of B cells were observed, which was characterized as decreased naive B cell (P = 0.012) and increased memory B cells (P = 0.001) and non-switched B cells (P = 0.012).The microbial community richness indicated by operational taxonomic units number, observed species and Chao1 estimator was marginally increased after FMT. Gut microbiome composition of discharged COVID-19 patients differed from that of the general population at both phylum and genera level, which was characterized with a lower proportion of Firmicutes (41.0%) and Actinobacteria (4.0%), higher proportion of Bacteroidetes (42.9%) and Proteobacteria (9.2%). FMT can partially restore the gut dysbiosis by increasing the relative abundance of Actinobacteria (15.0%) and reducing Proteobacteria (2.8%) at the phylum level. At the genera level, Bifidobacterium and Faecalibacterium had significantly increased after FMT. CONCLUSIONS: After FMT, altered peripheral lymphocyte subset, restored gut microbiota and alleviated gastrointestinal disorders were observe, suggesting that FMT may serve as a potential therapeutic and rehabilitative intervention for the COVID-19.


Subject(s)
B-Lymphocyte Subsets , COVID-19/complications , Dysbiosis/therapy , Fecal Microbiota Transplantation , Gastrointestinal Diseases/therapy , Gastrointestinal Microbiome , Aged , Bacteroidetes , Bifidobacterium , COVID-19/immunology , Dysbiosis/microbiology , Faecalibacterium , Female , Gastrointestinal Diseases/microbiology , Humans , Male , Middle Aged , Patient Discharge , Proteobacteria , SARS-CoV-2 , Young Adult
5.
Social Work Education ; : 1-8, 2020.
Article | Taylor & Francis | ID: covidwho-759710
SELECTION OF CITATIONS
SEARCH DETAIL